
The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss meds, a new study finds. Data on almost 17 million adults nationwide showed the obesity rate — which has been rising for years — fell from 46.2% of adults in 2021 to 45.6% in 2023, Harvard University researchers report. Obesity was defined as having a body mass index (BMI) of 30 or above. At the same time, the use of GLP-1 medications like Wegovy and Zepbound has surged, although the researchers said it’s not possible to confirm a cause-and-effect relationship between the trends. Still, they noted that, “The most notable decrease [in obesity] was in the South, which had the highest observed…dispensing rate,” for GLP-1 medications. The study was led by Benjamin Rader, an assistant professor of anesthesia at Harvard Medical School, and published Dec. 13 in the journal JAMA Health Forum. As Rader’s team noted, “the prevalence of obesity in the U.S. has increased for several decades. Some long-term forecasts estimate that this upward trajectory will continue, while others forecast a plateau.” The introduction of GLP-1 meds like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) into the marketplace has been a perhaps unexpected new factor in recent years, however. Sales of the injected medications have soared, and the results in terms of weight… read on > read on >